查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108380

生物製藥CMO市場分析及預測（至2035年）：依類型、產品、服務、技術、應用、過程、最終用戶及階段分類

Biopharmaceutical CMO Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Process, End User, Stage
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球生物製藥CMO市場預計將從2025年的187億美元成長到2035年的814億美元，CAGR為15.8%。該市場集中度適中，全球領先的契約製造公司正不斷擴大其生物製藥產能、先進生產技術和端到端開發服務，以滿足日益成長的外包需求。儘管哺乳動物細胞培養仍然是主要的生產平台，單株抗體、重組蛋白和新一代生物製藥的產量不斷成長，但細胞和基因療法的生產崛起為一個高成長領域。市場競爭主要圍繞產能擴張、一次性生物過程、連續生產和一體化CDMO（開發和受託製造）能力。例如，三星生物製劑公司於2025年1月在摩根大通醫療保健大會上宣布，將啟用第五工廠，擴大生物園區二期，並推出專門的抗體藥物偶聯物（ADC）生產服務。此舉目的是增強公司在全球的合約研發生產（CDMO）能力，並滿足日益成長的生物製藥外包需求。

依類型分析市場，哺乳動物細胞在2025年仍將主導生物製藥CMO市場。這是因為哺乳動物細胞廣泛應用於複雜生物製藥的生產，尤其是單株抗體、重組蛋白和高活性治療性生物製藥。哺乳動物細胞表達系統，特別是中國倉鼠卵巢（CHO）細胞，能夠實現卓越的蛋白質折疊、轉譯後修飾和糖基化模式，這對於生產高品質生物製藥非常重要。生物製藥的商業化程度不斷提高、生物相似藥生產的擴張以及大規模生物製造活動外包的日益增多，進一步推動了對基於哺乳動物細胞的契約製造的需求。高產細胞株的開發、生物過程的最佳化以及對大規模生產能力的持續投資，進一步鞏固了該領域在市場中的主導地位。

市場區隔
類型 哺乳動物、微生物、植物、酵母、昆蟲、其他
產品 單株抗體、重組蛋白、疫苗、細胞療法、基因療法、其他
服務 過程開發、分析和品管（QC）研究、包裝、填充和精加工過程、其他
技術 一次性技術、連續加工、上游過程、下游過程、其他
用途 腫瘤學、心血管疾病、神經病學、感染疾病、免疫學、其他
過程 上游、下游、其他
最終用戶 製藥公司、生技公司、研究機構、其他
階段 臨床前階段、臨床階段、商業化階段、其他

從產品細分來看，細胞治療領域預計將在預測期內呈現最高的成長率，這主要得益於個人化醫療的快速發展、獲準的先進治療藥物（ATMP）數量的增加以及對再生醫學和免疫療法投資的加大。尤其是在腫瘤學和罕見疾病領域，自體和異體細胞療法的需求不斷成長，促使製藥和生物技術公司將專業生產外包給經驗豐富的合約生產商（CMO）。自動化生產平台的日益普及、嚴格的監管要求以及對高度可控生產環境的需求，都在加速外包活動的發展。臨床研發管線的擴展和新一代細胞療法的商業化預計將進一步推動該領域的強勁成長。

區域概覽

2025年，北美主導生物製藥合約生產組織（CMO）市場。這得益於其成熟的生物製藥產業、全球合約研發生產組織（CDMO）和生物技術公司的強大影響力，以及對生物製藥、細胞和基因療法以及先進製造技術的巨額投資。美國憑藉其豐富的生物製藥產品線、有利的法規環境、高額的研發投入以及製藥和生物技術公司廣泛的外包業務，在區域市場中佔據領先地位。加拿大透過擴大生物製造基礎設施和政府對生命科學領域的支持，也做出了貢獻。對大型生產設施的持續投資以及生物製藥商業化的進展，進一步鞏固了北美的主導地位。

預計亞太地區將在預測期內實現最快成長，這主要得益於生物製藥產能的快速擴張、全球製藥公司外包業務的增加以及政府支持生物技術生產的利好政策。中國、印度、韓國和新加坡正崛起為主要的生物製造地，這得益於其具有競爭力的製造成本、熟練的勞動力以及對生物製藥、生物相似藥、疫苗和細胞基因療法的巨額投資。臨床研究活動的拓展、監管協調的推進以及符合GMP認證的生產設施數量的持續成長，預計將在整個預測期內進一步加速該地區的市場成長。

主要趨勢和促進因素

擴大整合式端對端CDMO服務的應用

生物製藥公司擴大與契約製造組織（CDMO）合作，這些組織提供涵蓋細胞株開發、過程最佳化、臨床生產、商業化生產、填充和包裝、分析測試、包裝以及法規遵循等一體化服務。這種端到端的外包模式降低了技術轉移風險，縮短了研發週期，並提高了生產效率。在生物製藥、生物相似藥、抗體藥物偶聯物（ADC）以及細胞和基因療法需求不斷成長的推動下，CDMO 透過提高產能、採用數位化製造平台和先進的生物過程技術來擴展其一體化服務能力，加快產品上市速度並提高供應鏈的柔軟性。

生物製藥和先進療法製造領域外包業務的擴張

生物製藥合約生產組織（CMO）市場的成長主要受製藥和生物技術公司將生物製藥、生物相似藥、疫苗和先進療法的製造外包不斷成長的推動。日益複雜的生產流程、高額的資本投資以及嚴格的監管標準，促使製藥研發公司尋求擁有先進生產技術和符合GMP認證設施的專業CMO的合作。生物製藥產品線的擴展、臨床試驗活動的活性化以及可擴展商業化生產需求的成長，進一步加速了外包合作的進程。對一次性生物過程、高產能生產設施和專業生產技術的持續投資，預計將在整個預測期內維持市場的強勁成長。

目錄

第1章 執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機會
  • 市場限制因素
  • 年複合成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 哺乳動物
    • 微生物
    • 植物
    • 酵母菌
    • 昆蟲
    • 其他
  • 市場規模及預測：依產品分類
    • 單株抗體
    • 重組蛋白
    • 疫苗
    • 細胞療法
    • 基因治療
    • 其他
  • 市場規模及預測：依服務分類
    • 過程開發
    • 分析和品管（QC）研究
    • 包裝
    • 填充和精加工過程
    • 其他
  • 市場規模及預測：依技術分類
    • 單次使用技術
    • 連續加工
    • 上游過程
    • 下游過程
    • 其他
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 心血管疾病
    • 神經病學
    • 感染疾病
    • 免疫學
    • 其他
  • 市場規模及預測：依過程分類
    • 上游
    • 下游
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 研究機構
    • 其他
  • 市場規模及預測：依階段分類
    • 臨床前階段
    • 臨床階段
    • 商業階段
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 定價和成本利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要公司的策略

第8章 公司簡介

  • Lonza
  • Samsung Biologics
  • Catalent
  • Boehringer Ingelheim
  • WuXi Biologics
  • Thermo Fisher Scientific
  • Fujifilm Diosynth BIoTechnologies
  • Siegfried Holding
  • Recipharm
  • AGC Biologics
  • Jubilant Biosys
  • Rentschler Biopharma
  • Patheon
  • Baxter BioPharma Solutions
  • Cytiva
  • KBI Biopharma
  • AbbVie Contract Manufacturing
  • Ajinomoto Bio-Pharma Services
  • Alcami
  • CordenPharma

第9章 關於我們

簡介目錄
Product Code: GIS21593

The global Biopharmaceutical CMO Market is projected to grow from $18.7 billion in 2025 to $81.4 billion by 2035, at a compound annual growth rate (CAGR) of 15.8%. The Biopharmaceutical CMO Market is moderately consolidated, with leading global contract manufacturing organizations expanding biologics production capacity, advanced manufacturing technologies, and end-to-end development services to meet rising outsourcing demand. Mammalian cell culture remains the dominant manufacturing platform, supported by increasing production of monoclonal antibodies, recombinant proteins, and next-generation biologics, while cell and gene therapy manufacturing is emerging as a high-growth area. Competition is centered on capacity expansion, single-use bioprocessing, continuous manufacturing, and integrated CDMO capabilities. For instance, in January 2025, Samsung Biologics announced at the 2025 J.P. Morgan Healthcare Conference that it would open Plant 5, expand Bio Campus II, and launch dedicated antibody-drug conjugate (ADC) manufacturing services to strengthen its global CDMO capabilities and meet growing biopharmaceutical outsourcing demand.

Based on Type, the Mammalian segment dominated the Biopharmaceutical CMO Market in 2025 due to its extensive use in the production of complex biologics, particularly monoclonal antibodies, recombinant proteins, and advanced therapeutic biologics. Mammalian cell expression systems, especially Chinese Hamster Ovary (CHO) cells, provide superior protein folding, post-translational modifications, and glycosylation patterns essential for producing high-quality biopharmaceuticals. The increasing commercialization of biologics, expanding biosimilar manufacturing, and growing outsourcing of large-scale biomanufacturing activities have further strengthened demand for mammalian-based contract manufacturing. Continuous investments in high-yield cell line development, bioprocess optimization, and large-scale production capacity continue to reinforce the segment's leading market position.

Market Segmentation
TypeMammalian, Microbial, Plant, Yeast, Insect, Others
ProductMonoclonal Antibodies, Recombinant Proteins, Vaccines, Cell Therapy, Gene Therapy, Others
ServicesProcess Development, Analytical and QC Studies, Packaging, Fill & Finish Operations, Others
TechnologySingle-Use Technology, Continuous Processing, Upstream Processing, Downstream Processing, Others
ApplicationOncology, Cardiovascular Diseases, Neurology, Infectious Diseases, Immunology, Others
ProcessUpstream, Downstream, Others
End UserPharmaceutical Companies, Biotechnology Companies, Research Organizations, Others
StagePreclinical, Clinical, Commercial, Others

Based on Product, the Cell Therapy segment is projected to register the fastest growth during the forecast period due to the rapid expansion of personalized medicine, increasing approvals of advanced therapy medicinal products (ATMPs), and rising investments in regenerative medicine and immunotherapy. Growing demand for autologous and allogeneic cell therapies, particularly for oncology and rare diseases, is driving pharmaceutical and biotechnology companies to outsource specialized manufacturing to experienced CMOs. Increasing adoption of automated manufacturing platforms, stringent regulatory requirements, and the need for highly controlled production environments are accelerating outsourcing activities. Expanding clinical pipelines and commercialization of next-generation cell therapies are expected to further drive the segment's robust growth.

Geographical Overview

North America dominated the Biopharmaceutical CMO Market in 2025, supported by its well-established biopharmaceutical industry, strong presence of global CDMOs and biotechnology companies, and significant investments in biologics, cell and gene therapies, and advanced manufacturing technologies. The United States leads the regional market owing to its extensive biologics pipeline, favorable regulatory environment, high R&D expenditure, and widespread outsourcing by pharmaceutical and biotechnology companies. Canada further contributes through expanding biomanufacturing infrastructure and government support for life sciences. Continuous investments in large-scale manufacturing facilities and increasing commercialization of biologics continue to strengthen North America's leadership position.

Asia-Pacific is projected to register the fastest growth during the forecast period due to rapidly expanding biopharmaceutical manufacturing capacity, increasing outsourcing from global pharmaceutical companies, and favorable government initiatives supporting biotechnology production. China, India, South Korea, and Singapore are emerging as major biomanufacturing hubs because of competitive manufacturing costs, skilled workforce, and significant investments in biologics, biosimilars, vaccines, and cell and gene therapies. Growing clinical research activities, increasing regulatory harmonization, and continuous expansion of GMP-certified manufacturing facilities are expected to further accelerate regional market growth throughout the forecast period.

Key Trends and Drivers

Growing Adoption of Integrated End-to-End CDMO Services:

Biopharmaceutical companies are increasingly partnering with contract manufacturing organizations that provide integrated services spanning cell line development, process optimization, clinical manufacturing, commercial-scale production, fill-finish, analytical testing, packaging, and regulatory support. This end-to-end outsourcing model reduces technology transfer risks, shortens development timelines, and improves manufacturing efficiency. Growing demand for biologics, biosimilars, antibody-drug conjugates (ADCs), and cell and gene therapies is encouraging CMOs to expand integrated service capabilities through capacity expansion, digital manufacturing platforms, and advanced bioprocessing technologies, enabling faster commercialization and greater supply chain flexibility.

Increasing Outsourcing of Biologics and Advanced Therapy Manufacturing:

The growth of the biopharmaceutical CMO market is primarily driven by increasing outsourcing of biologics, biosimilars, vaccines, and advanced therapies by pharmaceutical and biotechnology companies. Rising manufacturing complexity, high capital investment requirements, and stringent regulatory standards are encouraging drug developers to leverage specialized CMOs with advanced manufacturing expertise and GMP-certified facilities. Expanding biologics pipelines, increasing clinical trial activity, and growing demand for scalable commercial manufacturing are further accelerating outsourcing partnerships. Continuous investments in single-use bioprocessing, high-capacity manufacturing facilities, and specialized production technologies are expected to sustain strong market growth throughout the forecast period.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Mammalian
    • 4.1.2 Microbial
    • 4.1.3 Plant
    • 4.1.4 Yeast
    • 4.1.5 Insect
    • 4.1.6 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Monoclonal Antibodies
    • 4.2.2 Recombinant Proteins
    • 4.2.3 Vaccines
    • 4.2.4 Cell Therapy
    • 4.2.5 Gene Therapy
    • 4.2.6 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Process Development
    • 4.3.2 Analytical and QC Studies
    • 4.3.3 Packaging
    • 4.3.4 Fill & Finish Operations
    • 4.3.5 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Single-Use Technology
    • 4.4.2 Continuous Processing
    • 4.4.3 Upstream Processing
    • 4.4.4 Downstream Processing
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Cardiovascular Diseases
    • 4.5.3 Neurology
    • 4.5.4 Infectious Diseases
    • 4.5.5 Immunology
    • 4.5.6 Others
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 Upstream
    • 4.6.2 Downstream
    • 4.6.3 Others
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Pharmaceutical Companies
    • 4.7.2 Biotechnology Companies
    • 4.7.3 Research Organizations
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Preclinical
    • 4.8.2 Clinical
    • 4.8.3 Commercial
    • 4.8.4 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 Process
      • 5.2.1.7 End User
      • 5.2.1.8 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 Process
      • 5.2.2.7 End User
      • 5.2.2.8 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 Process
      • 5.2.3.7 End User
      • 5.2.3.8 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 Process
      • 5.3.1.7 End User
      • 5.3.1.8 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 Process
      • 5.3.2.7 End User
      • 5.3.2.8 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 Process
      • 5.3.3.7 End User
      • 5.3.3.8 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 Process
      • 5.4.1.7 End User
      • 5.4.1.8 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 Process
      • 5.4.2.7 End User
      • 5.4.2.8 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 Process
      • 5.4.3.7 End User
      • 5.4.3.8 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 Process
      • 5.4.4.7 End User
      • 5.4.4.8 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 Process
      • 5.4.5.7 End User
      • 5.4.5.8 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 Process
      • 5.4.6.7 End User
      • 5.4.6.8 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 Process
      • 5.4.7.7 End User
      • 5.4.7.8 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 Process
      • 5.5.1.7 End User
      • 5.5.1.8 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 Process
      • 5.5.2.7 End User
      • 5.5.2.8 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 Process
      • 5.5.3.7 End User
      • 5.5.3.8 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 Process
      • 5.5.4.7 End User
      • 5.5.4.8 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 Process
      • 5.5.5.7 End User
      • 5.5.5.8 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 Process
      • 5.5.6.7 End User
      • 5.5.6.8 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 Process
      • 5.6.1.7 End User
      • 5.6.1.8 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 Process
      • 5.6.2.7 End User
      • 5.6.2.8 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 Process
      • 5.6.3.7 End User
      • 5.6.3.8 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 Process
      • 5.6.4.7 End User
      • 5.6.4.8 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 Process
      • 5.6.5.7 End User
      • 5.6.5.8 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Lonza
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Samsung Biologics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Catalent
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Boehringer Ingelheim
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 WuXi Biologics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Thermo Fisher Scientific
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Fujifilm Diosynth Biotechnologies
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Siegfried Holding
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Recipharm
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 AGC Biologics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Jubilant Biosys
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Rentschler Biopharma
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Patheon
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Baxter BioPharma Solutions
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Cytiva
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 KBI Biopharma
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 AbbVie Contract Manufacturing
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Ajinomoto Bio-Pharma Services
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Alcami
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 CordenPharma
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us